Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.
You may also be interested in...
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
FDA Regulation Of Homeopathics Does Not Pre-empt Damages Claims – Court
A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.